Hemostatic Balance in Hemophilia

CME

Research Focus: Achieving Hemostatic Balance in Hemophilia With Emerging Therapies

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: March 21, 2024

Expiration: March 20, 2025

Miguel A. Escobar
Miguel A. Escobar, MD
Margareth C. Ozelo
Margareth C. Ozelo, MD, PhD
Runhui Wu
Runhui Wu, MD, PhD

Activity

Progress
1 2
Course Completed

References

  1. Rodriguez-Merchan EC. Musculoskeletal complications of hemophilia. HSS J. 2010;6:37
  2. Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition [published correction appears in Haemophilia. 2021;27:699]. Haemophilia. 2020;26(suppl 6):1-158.
  3. MDedge. Nationwide hematologists shortage: what’s being done? mdedge.com/hematology-oncology/article/265457/bleeding-disorders/nationwide-hematologists-shortage-whats-being. Accessed March 13, 2024.
  4. Okide CC, Eseadi C, Koledoye UL, et al. Challenges facing community-dwelling adults with hemophilia: Implications for community-based adult education and nursing. J Int Med Res. 2020;48:300060519862101.
  5. Pratap R, Misra M, N V, et al. The existing scenario of haemophilia care in Canada and China - a review. Hematol Transfus Cell Ther. 2020;42:356-364.
  6. Lee EKP, Poon P, Yip BHK, et al. Global burden, regional differences, trends, and health consequences of medication nonadherence for hypertension during 2010 to 2020: a meta-analysis involving 27 million patients. J Am Heart Assoc. 2022;11:e026582.
  7. Muhammad N, Ullah SR, Nagi TK, et al. Factors associated with non-adherence to anti-depressant medication in adults: a systematic review and meta-analysis. Cureus. 2023;15:e37828.
  8. Aberhe W, Hailay A, Zereabruk K, et al. Non-adherence to inhaled medications among adult asthmatic patients in Ethiopia: a systematic review and meta-analysis. Asthma Res Pract. 2020;6:12.
  9. Ahmed A, Dujaili JA, Jabeen M, et al. Barriers and enablers for adherence to antiretroviral therapy among people living with HIV/AIDS in the era of COVID-19: a qualitative study from Pakistan. Front Pharmacol. 2022;12:807446.
  10. Adult Meducation. Overview of medication adherence: where are we today? adultmeducation.com/OverviewofMedicationAdherence_4.html. Accessed March 13, 2024.
  11. Thornburg CD, Duncan NA. Treatment adherence in hemophilia. Patient Prefer Adherence. 2017;11:1677-1686.
  12. Castro HE, Briceño MF, Casas CP, et al. The history and evolution of the clinical effectiveness of haemophilia type a treatment: a systematic review. Indian J Hematol Blood Transfus. 2014;30:1-11.
  13. Mancuso ME, Oldenburg J, Boggio L, et al. High adherence to prophylaxis regimens in haemophilia B patients receiving rIX-FP: evidence from clinical trials and real-world practice. Haemophilia. 2020;26:637-642.
  14. Anghel LA, Farcas AM, Oprean RN. An overview of the common methods used to measure treatment adherence. Med Pharm Rep. 2019;92:117-122.
  15. du Treil S, Rice J, Leissinger CA. Quantifying adherence to treatment and its relationship to quality of life in a well-characterized haemophilia population. Haemophilia. 2007;13:493-501.
  16. Duncan NA, Kronenberger WG, Roberson CP, et al. VERITAS-PRN: a new measure of adherence to episodic treatment regimens in haemophilia. Haemophilia. 2010;16:47-53.
  17. Duncan N, Kronenberger W, Roberson C, et al. VERITAS-Pro: a new measure of adherence to prophylactic regimens in haemophilia. Haemophilia. 2010;16:247-255.
  18. Lindvall K, Colstrup L, Wollter IM, et al. Compliance with treatment and understanding of own disease in patients with severe and moderate haemophilia. Haemophilia. 2006;12:47-51.
  19. Lindvall K, Colstrup L, Loogna K, et al. Knowledge of disease and adherence in adult patients with haemophilia. Haemophilia. 2010;16:592-596.
  20. Hoefnagels JW, Schrijvers LH, Leebeek FWG, et al. Adherence to prophylaxis and its association with activation of self-management and treatment satisfaction. Haemophilia. 2021;27:581-590.
  21. Geraghty S, Dunkley T, Harrington C, et al. Practice patterns in haemophilia A therapy -- global progress towards optimal care. Haemophilia. 2006;12:75-81.
  22. Petrini P. Identifying and overcoming barriers to prophylaxis in the management of haemophilia. Haemophilia. 2007;13(suppl 2):16-22.
  23. De Moerloose P, Urbancik W, Van Den Berg HM, et al. A survey of adherence to haemophilia therapy in six European countries: results and recommendations. Haemophilia. 2008;14:931-938.
  24. Thornburg CD. Prophylactic factor infusions for patients with hemophilia: challenges with treatment adherence. J Coagul Disord. 2010;000:000.
  25. Ar MC, Balkan C, Kavaklı K. Extended half-life coagulation factors: a new era in the management of hemophilia patients. Turk J Haematol. 2019;36:141-154.
  26. Mannucci PM. Hemophilia therapy: the future has begun. Haematologica. 2020;105:545-553.
  27. von Mackensen S, Kalnins W, Krucker J, et al. Haemophilia patients’ unmet needs and their expectations of the new extended half-life factor concentrates. Haemophilia. 2017;23:566-574.
  28. McCary I, Guelcher C, Kuhn J, et al. Real-world use of emicizumab in patients with haemophilia A: bleeding outcomes and surgical procedures. Haemophilia. 2020;26:631-636.
  29. Mason JA, Young G. Emicizumab prophylaxis in infants with severe haemophilia A without inhibitors: Illustrative real-world cases to support shared decision-making. Haemophilia. 2021;27:724-729.
  30. Castaman G. The benefits of prophylaxis in patients with hemophilia B. Expert Rev Hematol. 2018;11:673-683.
  31. Emicizumab-kxwh [prescribing information]. South San Francisco, CA: Genentech, Inc., a Member of the Roche Group; 2023.
  32. Callaghan MU, Negrier C, Paz-Priel I, et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies [published correction appears in Blood. 2023;142:1329]. Blood. 2021;137:2231-2242.
  33. Patel AM, Corman SL, Chaplin S, et al. Economic impact model of delayed inhibitor development in patients with hemophilia A receiving emicizumab for the prevention of bleeding events. J Med Econ. 2019;22:1328-1337.
  34. Pipe SW, Collins P, Dhalluin C, et al. Emicizumab prophylaxis for the treatment of infants with severe hemophilia A without factor VIII inhibitors: results from the interim analysis of the HAVEN 7 study. Presented at: 2022 American Society of Hematology Annual Meeting and Exposition; December 10-13, 2022. Abstract 187.
  35. Schmitt C, Adamkewicz JI, Xu J, et al. Pharmacokinetics and pharmacodynamics of emicizumab in persons with hemophilia a with factor VIII inhibitors: HAVEN 1 study. Thromb Haemost. 2021;121:351-360.
  36. Normahani P, Sounderajah V, Harrop-Griffiths W, et al. Achieving good-quality consent: review of literature, case law and guidance. BJS Open. 2020;4:757-763.
  37. Willyard C. Thrombosis: balancing act. Nature. 2014;515:S168-S169.
  38. Chowdary P. Inhibition of tissue factor pathway inhibitor (TFPI) as a treatment for haemophilia: rationale with focus on concizumab [published correction appears in Drugs. 2018;78:891]. Drugs. 2018;78:881-890.
  39. Peters R, Harris T. Advances and innovations in haemophilia treatment. Nat Rev Drug Discov. 2018;17:493-508.
  40. Verhagen MJA, Valke LLFG, Schols SEM. Thrombin generation for monitoring hemostatic therapy in hemophilia A: a narrative review. J Thromb Haemost. 2022;20:794-805.
  41. Mast AE, Ruf W. Regulation of coagulation by tissue factor pathway inhibitor: Implications for hemophilia therapy. J Thromb Haemost. 2022;20:1290-1300.
  42. Kwak H, Lee S, Jo S, et al. MG1113, a specific anti-tissue factor pathway inhibitor antibody, rebalances the coagulation system and promotes hemostasis in hemophilia. Res Pract Thromb Haemost. 2020;4:1301-1312.
  43. Mancuso ME, Ingham SJM, Kunze M. Befovacimab, an anti-tissue factor pathway inhibitor antibody: early termination of the multiple-dose, dose-escalating phase 2 study due to thrombosis. Haemophilia. 2022;28:702-712.
  44. Shapiro AD, Angchaisuksiri P, Astermark J, et al. Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. Blood. 2019;134:1973-1982.
  45. Shapiro AD, Angchaisuksiri P, Astermark J, et al. Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors. Blood Adv. 2022;6:3422-3432.
  46. Valer Seremetis S, Cepo K, Skovgaard Rasmussen J, et al. Risk mitigation strategy for concizumab clinical trials after pause due to non-fatal thrombotic events. Presented at: 2020 American Society of Hematology Annual Meeting and Exposition; December 5-8, 2020. Abstract 1796.
  47. Matsushita T, Shapiro A, Abraham A, et al. Phase 3 trial of concizumab in hemophilia with inhibitors. N Engl J Med. 2023;389:783-794.
  48. Government of Canada Drug and Health Product Portal. Summary basis of decision for Alhemo. dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD1685635290781. Accessed March 13, 2024.
  49. KEGG Drug Database. New drug approvals in the USA, Europe and Japan. genome.jp/kegg/drug/br08328.html. Accessed March 13, 2024. 
  50. Mahlangu JN, Lamas JL, Morales JC, et al. A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia. Br J Haematol. 2023;200:229-239.
  51. Matino D, Acharya S, Palladino A, et al. Efficacy and safety of the anti-tissue factor pathway inhibitor marstacimab in participants with severe hemophilia without inhibitors: results from the phase 3 basis trial. Presented at: 2023 American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023. Abstract 285.
  52. Pasi KJ, Lissitchkov T, Mamonov V, et al. Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-results of the phase 1 inhibitor cohort. J Thromb Haemost. 2021;19:1436-1446.
  53. Franchini M, Mannucci PM. Non-factor replacement therapy for haemophilia: a current update. Blood Transfus. 2018;16:457-461.
  54. Tiede A. Thromboembolic risks of non-factor replacement therapies in hemophilia. Hamostaseologie. 2017;37:307-310.
  55. Young G, Lenting PJ, Croteau SE, et al. Antithrombin lowering in hemophilia: a closer look at fitusiran. Res Pract Thromb Haemost. 2023;7:100179.
  56. Pipe S, Ragni MV, Négrier C, et al. Fitusiran, an RNAi therapeutic targeting antithrombin to restore hemostatic balance in patients with hemophilia A or B with or without inhibitors: management of acute bleeding events. Blood. 2019;134(suppl 1):1138.
  57. Srivastava A, Rangarajan S, Kavakli K, et al. Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial. Lancet Haematol. 2023;10:e322-e332.
  58. Young G, Srivastava A, Kavakli K, et al. Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial. Lancet. 2023;401:1427-1437.
  59. Kenet G, Nolan B, Zulfikar B, et al. A phase 3 study (ATLAS-PPX) to evaluate efficacy and safety of fitusiran, an siRNA therapeutic, in people with haemophilia A or B who have switched from prior factor or bypassing agent prophylaxis. Presented at: International Society on Thrombosis and Haemostasis 2022 Congress; July 9-13, 2022. Abstract LB 01.1.
  60. Pipe S, Srivastava A, Klamroth R, et al. Fitusiran, an investigational siRNA therapeutic targeting antithrombin: analysis of antithrombin levels and thrombin generation from a phase 3 study in people with hemophilia A or B without inhibitors. Presented at: International Society on Thrombosis and Haemostasis 2022 Congress; July 9-13, 2022. Abstract OC 50.2.
  61. Baglin T, Huntington JA, Koch A, et al. Serpin-PC in persons with severe hemophilia (PwH): updated results from a multicenter multi-part, first-in-human study. Blood. 2023;142(suppl 1):2619.
  62. Baglin T, Koch A, Mocanu I, et al. SerpinPC in persons with severe hemophilia (PwH): updated results from a multi-center, multi-part, first-in-human study. Presented at: European Association for Haemophilia and Allied Disorders 2024 Congress; February 6-9, 2024. Abstract OR11.
  63. Arruda VR, Doshi BS, Samelson-Jones BJ. Novel approaches to hemophilia therapy: successes and challenges [published correction appears in Blood. 2018;131:2995]. Blood. 2017;130:2251-2256.
  64. US Centers for Disease Control and Prevention. Treatment of hemophilia. cdc.gov/ncbddd/hemophilia/treatment.html. Accessed March 13, 2024.
  65. Arruda VR, Doshi BS, Samelson-Jones BJ. Emerging therapies for hemophilia: controversies and unanswered questions. F1000Res. 2018;7:F1000 Faculty Rev-489.
  66. Skinner MW, Nugent D, Wilton P, et al. Achieving the unimaginable: health equity in haemophilia. Haemophilia. 2020;26:17-24.
  67. Hermans C, Pierce GF. Towards achieving a haemophilia-free mind. Haemophilia. 2023;29:951-953.
  68. Ghosh K, Ghosh K. Management of haemophilia in developing countries: challenges and options. Indian J Hematol Blood Transfus. 2016;32:347-355.
  69. Curtis R, Roberts JC, Crook N, et al. Trends in prescribing practices for management of haemophilia: 1999-2021. Haemophilia. 2023;29:761-769.
  70. Guan T, Ai D, Zhao N, et al. Treatment-related outcome from patient report outcome (PRO) of children with severe and moderate hemophilia A in China: an analysis report of registration data from patient organization “hemophilia home care center”. Haemophilia. 2023;29:1467-1474.
  71. Ellsworth P, Ma A. Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates? Hematology Am Soc Hematol Educ Program. 2021;2021:219-225.
  72. Cortesi PA, Castaman G, Trifirò G, et al. Cost-effectiveness and budget impact of emicizumab prophylaxis in haemophilia A patients with inhibitors. Thromb Haemost. 2020;120:216-228.
  73. Nathwani AC. Gene therapy for hemophilia. Hematology Am Soc Hematol Educ Program. 2022;2022:569-578.
  74. Nogami K, Fujii T, Sawada A, et al. Association of physical activity with bleeding events and safety in patients with haemophilia A starting emicizumab prophylaxis: an interim analysis of the TSUBASA study. Int J Hematol. 2024;119:14-23.
  75. Shima M, Amano K, Ogawa Y, et al. A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A. J Thromb Haemost. 2023;21:534-545.
  76. Matsushita T, Suzuki N, Nagao A, et al. AKATSUKI study: a prospective, multicentre, phase IV study evaluating the safety of emicizumab under and immediately after immune tolerance induction therapy in persons with congenital haemophilia A with factor VIII inhibitors. BMJ Open. 2022;12:e057018.
  77. Ogiwara K, Taki M, Suzuki T, et al. Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in haemophilia A with inhibitor (UNEBI Study): multicentre open-label non-randomised clinical trial. BMJ Open. 2022;12:e056922.
  78. Leebeek FWG, Miesbach W. Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues. Blood. 2021;138:923-931.
  79. Krumb E, Lambert C, Hermans C. Patient selection for hemophilia gene therapy: real-life data from a single center. Res Pract Thromb Haemost. 2021;5:390-394.
  80. Chou SC, Hsu YC, Lin SW. Gene therapy for hemophilia, a clinical viewpoint. J Formos Med Assoc. 2023;122:1101-1110.
  81. Bolous NS, Chen Y, Wang H, et al. The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspective. Blood. 2021;138:1677-1690.
  82. Mahlangu J, Iorio A, Kenet G. Emicizumab state-of-the-art update. Haemophilia. 2022;28(suppl 4):103-110.
  83. Bertamino M, Riccardi F, Banov L, et al. Hemophilia care in the pediatric age. J Clin Med. 2017;6:54.
  84. National Bleeding Disorders Foundation. Frequently asked questions. hemophilia.org/bleeding-disorders-a-z/treatment/future-therapies/frequently-asked-questions. Accessed March 13, 2024.
  85. Valentino LA, Kaczmarek R, Pierce GF, et al. Hemophilia gene therapy: first, do no harm. J Thromb Haemost. 2023;21:2354-2361.
  86. Butterfield JSS, Hege KM, Herzog RW, et al. A molecular revolution in the treatment of hemophilia. Mol Ther. 2020;28:997-1015.
  87. Patil R, Shanmukhaiah C, Gogtay NJ, et al. Low-dose emicizumab prophylaxis in patients with severe hemophilia A: a retrospective study bringing new hope for our patients. J Thromb Haemost. 2023:S1538-7836(23)00925-X.